J&J CEO Says Tax Policy, Not Tariffs, Is The Most Effective To Build US Manufacturing Capacity

April 15 (Reuters) - Johnson & Johnson JNJ.N:

• J&J EXEC SAYS EXPECTS APPROVAL OF CAPLYTA LATER THIS YEAR AS AN ADJUNCTIVE TREATMENT FOR MAJOR DEPRESSIVE DISORDER - CONF CALL

• J&J EXEC SAYS IMPLEMENTING A RESTRUCTURING PROGRAM TO SIMPLIFY AND FOCUS THE OPERATIONS OF ITS SURGERY BUSINESS - CONF CALL

• J&J EXEC SAYS PLAN TO EXIT CERTAIN NON STRATEGIC PRODUCT LINES GLOBALLY & OPTIMIZE SELECT SITES ACROSS THE NETWORK FOR SURGERY BUSINESS

• J&J EXEC SAYS CO EXPECTS SOME MODEST SHORT TERM REVENUE DISRUPTION IN SURGERY BUSINESS OF ABOUT $250 MILLION OVER THE NEXT TWO YEARS

• J&J EXEC SAYS RESTRUCTURING PROGRAM FOR SURGERY BUSINESS IS EXPECTED TO BE COMPLETED IN 2027 WITH COST ESTIMATED AT ABOUT $900 MILLION

• J&J CEO SAYS "NOT TARIFFS, BUT TAX POLICY" IS THE MOST EFFECTIVE WAY TO BUILD MANUFACTURING CAPACITY IN THE US FOR MEDICAL DEVICES AND PHARMACEUTICALS

• J&J CEO SAYS PHARMACEUTICALS "TARIFFS CAN CREATE DISRUPTIONS IN THE SUPPLY CHAIN, LEADING TO SHORTAGES"